Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.38 |
| ▸ | MLYCD | O95822 | 1/20 | 0.38 |
| ▸ | POLQ | O75417 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6828600 | 0.84 | MLYCD (0.38) | SLC6A2SLC6A4NR1H3MLYCDPOLQ | |
| SCHEMBL2754132 | 0.79 | NR1H2 (0.45) | NR1H3ALDH1A1SMN1; SMN2TP53KMT2A | |
| SCHEMBL1818385 | 0.77 | ALDH1A1 (0.46) | SLC6A2SLC6A4ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL8586520 | 0.74 | ALOX5 (0.43) | SLC6A2SLC6A4ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1821413 | 0.74 | ALOX5 (0.43) | SLC6A2SLC6A4ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL11760439 | 0.73 | SLC6A2 (0.45) | SLC6A2SLC6A4ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL1821353 | 0.73 | SLC6A2 (0.45) | SLC6A2SLC6A4ALDH1A1SMN1; SMN2LMNA | |
| Carbamic Acid SCHEMBL27977071 | 0.72 | ALDH1A1 (0.46) | SLC6A2SLC6A4MLYCDALDH1A1SMN1; SMN2 | |
| SCHEMBL31467993 | 0.71 | SLC6A2 (0.44) | SLC6A2SLC6A4ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL3211903 | 0.68 | SLC6A2 (0.59) | SLC6A2SLC6A4ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-20160185725-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140155396-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. | 2014-06-05 | — | — | US | disclosed |
| US-20140155378-A9 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130252940-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8497284-B2 | C-met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8476298-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20120184523-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-8178532-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-7579473-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | SLC6A2 3028/4885SLC6A4 1181/4885NR1H3 3168/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | SLC6A2 3028/4885SLC6A4 1181/4885NR1H3 3168/4885 |
| US-20140155378-A9 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | SLC6A2 3458/4885SLC6A4 1625/4885NR1H3 3553/4885 |
| US-20140155396-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | SLC6A2 3458/4885SLC6A4 1625/4885NR1H3 3553/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | SLC6A2 3028/4885SLC6A4 1181/4885NR1H3 3168/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | SLC6A2 3028/4885SLC6A4 1181/4885NR1H3 3168/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | SLC6A2 3028/4885SLC6A4 1181/4885NR1H3 3168/4885 |
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | SLC6A2 3477/4885SLC6A4 1634/4885NR1H3 3516/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | SLC6A2 3458/4885SLC6A4 1625/4885NR1H3 3553/4885 |
| US-20160185725-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | SLC6A2 3458/4885SLC6A4 1625/4885NR1H3 3553/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | SLC6A2 3458/4885SLC6A4 1625/4885NR1H3 3553/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | SLC6A2 3028/4885SLC6A4 1181/4885NR1H3 3168/4885 |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | SLC6A2 3477/4885SLC6A4 1634/4885NR1H3 3516/4885 |
| US-20120184523-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | SLC6A2 3458/4885SLC6A4 1625/4885NR1H3 3553/4885 |
| US-20130252940-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | SLC6A2 3458/4885SLC6A4 1625/4885NR1H3 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.